We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: atopic dermatitis
MedXY News
EnglishTag

atopic dermatitis

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Unveiling Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: Insights from a Large Prospective BioDay Cohort
Dermatologyatopic dermatitisdupilumab

Unveiling Dupilumab-Associated Ocular Surface Disease in Atopic Dermatitis: Insights from a Large Prospective BioDay Cohort

By MedXY|Sep 12, 2026

This study reveals that 30.7% of atopic dermatitis patients treated with dupilumab develop ocular surface disease, despite prevalent ocular symptoms at baseline and increased ophthalmic treatment during therapy, linked to reduced conjunctiv

Equivalence of Online and In-Person Care in Managing Atopic Dermatitis: Insights from a Large Randomized Trial
Dermatologyatopic dermatitis
telehealth

Equivalence of Online and In-Person Care in Managing Atopic Dermatitis: Insights from a Large Randomized Trial

By MedXY|Aug 27, 2026

A randomized clinical trial shows online team-based care is as effective as conventional in-person treatment for atopic dermatitis, offering an accessible alternative for chronic disease management.

Early Respiratory Infection Burden and Atopic Dermatitis in Childhood: Insights from Prospective Birth Cohorts
Clinical Updateschildhoodatopic dermatitis

Early Respiratory Infection Burden and Atopic Dermatitis in Childhood: Insights from Prospective Birth Cohorts

By MedXY|Aug 20, 2026

Emerging evidence from prospective birth cohorts reveals a dose-dependent association between early respiratory infections and the risk of childhood atopic dermatitis, independent of genetic predisposition and antibiotic exposure.

Early Prediction of Dupilumab Efficacy in Facial Atopic Dermatitis via Reflectance Confocal Microscopy and Deep Learning
Allergy & Immunologyatopic dermatitisfacial lesions

Early Prediction of Dupilumab Efficacy in Facial Atopic Dermatitis via Reflectance Confocal Microscopy and Deep Learning

By MedXY|Aug 12, 2026

Reflectance confocal microscopy features at week 4 post-dupilumab treatment, combined with deep learning analysis, enable non-invasive prediction of therapeutic response in facial atopic dermatitis patients.

Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies
Allergy & ImmunologyAbrocitinibatopic dermatitis

Optimizing Long-Term Management in Moderate-to-Severe Atopic Dermatitis: Real-World Evidence on 24-Week Abrocitinib Tapering Strategies

By MedXY|Jul 12, 2026

This article reviews a retrospective study evaluating the feasibility and outcomes of a 24-week abrocitinib tapering regimen in moderate-to-severe atopic dermatitis, comparing dose reduction versus interval extension approaches and their im

Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis
Allergy & ImmunologyAbrocitinibatopic dermatitis

Feasibility and Comparative Outcomes of 24-Week Abrocitinib Tapering in Moderate-to-Severe Atopic Dermatitis

By MedXY|Jul 12, 2026

This study evaluates the successful 24-week tapering of abrocitinib in moderate-to-severe atopic dermatitis patients, comparing dose reduction versus interval extension tapering regimens and demonstrating high feasibility with substantial d

Large-Scale Meta-Analysis Finds Higher Influenza and Shingles Risk with JAK-STAT Inhibitors
Dermatologyatopic dermatitisInfection Risk

Large-Scale Meta-Analysis Finds Higher Influenza and Shingles Risk with JAK-STAT Inhibitors

By MedXY|May 27, 2026

A large meta-analysis found JAK-STAT inhibitors slightly increased influenza, bronchitis, and herpes zoster risk, especially in atopic dermatitis, while serious and opportunistic infections were not significantly increased.

Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models
Allergy & Immunologyatopic dermatitisChronic Pruritus

Sopoongsan Attenuates Chronic Pruritus via STAT1 Inhibition: Evidence from a Randomized Pilot Trial and Translational Models

By MedXY|Mar 6, 2026

A pilot randomized controlled trial and translational study demonstrate that Sopoongsan (SPS) effectively reduces chronic upper body pruritus in atopic and seborrheic dermatitis by inhibiting STAT1-mediated inflammatory pathways, offering a

Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment
Allergy & Immunologyatopic dermatitisdermatology

Pumecitinib 3% Gel Shows Robust Efficacy and Minimal Systemic Absorption in Mild-to-Moderate Atopic Dermatitis Treatment

By MedXY|Mar 5, 2026

A Phase IIb clinical trial demonstrates that pumecitinib 3% gel significantly improves skin clearance in adults with mild-to-moderate atopic dermatitis. Twice-daily application proved superior to once-daily dosing, maintaining a favorable s

Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis
Allergy & Immunologyatopic dermatitisImmunomodulation

Beyond Th2: Single-Dose Aletekitug Targets IL-18 to Deliver Sustained Clinical and Molecular Remission in Atopic Dermatitis

By MedXY|Mar 5, 2026

A phase 1/2 study reveals that a single dose of aletekitug, an anti-IL-18 antibody, provides durable clinical improvement and broad molecular modulation in moderate-to-severe atopic dermatitis, targeting pathways beyond traditional Type 2 i

Bathing Frequency and Eczema Severity: Analysis of the Eczema Bathing Citizen Science Randomized Controlled Trial
Clinical Updatesatopic dermatitisEczema

Bathing Frequency and Eczema Severity: Analysis of the Eczema Bathing Citizen Science Randomized Controlled Trial

By MedXY|Mar 5, 2026

A pragmatic RCT comparing weekly versus daily bathing in 438 eczema patients found no significant difference in symptom severity, supporting patient autonomy in choosing hygiene routines.

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial
Allergy & Immunologyatopic dermatitisAzathioprine

Baricitinib Demonstrates Superior Efficacy Over Azathioprine in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Randomized Head-to-Head Trial

By MedXY|Mar 5, 2026

A randomized trial (NCT05969730) shows that baricitinib plus topical corticosteroids significantly outperformed azathioprine in achieving EASI 75 at 12 weeks (65% vs. 15%) in patients with moderate-to-severe atopic dermatitis, with both tre

Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial
Allergy & Immunologyatopic dermatitisclinical trial

Antenatal Prebiotic Supplementation Fails to Prevent Atopic Dermatitis in High-Risk Infants: Insights from the PREGRALL Trial

By MedXY|Mar 5, 2026

The multicenter PREGRALL trial demonstrates that maternal intake of galacto-oligosaccharide/inulin prebiotics from mid-gestation does not reduce the incidence of atopic dermatitis or allergic sensitization in high-risk infants by age one, c

Bridging the Gap: A New Evidence-Based Patient Decision Aid for Systemic Atopic Dermatitis Therapy
Allergy & Immunologyatopic dermatitisShared Decision-Making

Bridging the Gap: A New Evidence-Based Patient Decision Aid for Systemic Atopic Dermatitis Therapy

By MedXY|Feb 21, 2026

Researchers have developed the first Patient Decision Aid (PDA) specifically for adult systemic atopic dermatitis treatments. The study highlights a ‘staged approach’ that balances clinician-driven data requirements with patient

Mapping the Atopic Landscape: New Meta-Analysis Identifies Key Drivers and Critical Windows for Childhood Food Allergy
Allergy & Immunologyatopic dermatitisfood allergy

Mapping the Atopic Landscape: New Meta-Analysis Identifies Key Drivers and Critical Windows for Childhood Food Allergy

By MedXY|Feb 10, 2026

This comprehensive systematic review and meta-analysis of 190 studies involving 2.8 million participants establishes a 4.7% incidence rate for childhood food allergy and identifies early atopic conditions, microbiome disruptions, and delaye

Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial
Clinical Updatesatopic dermatitisclinical trials

Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial

By MedXY|Jan 29, 2026

This review synthesizes findings from a Phase 2 trial of ICP-332, a novel TYK2 inhibitor, demonstrating significant EASI score improvements and a manageable safety profile in moderate to severe atopic dermatitis.

High-Dose Prenatal Vitamin D and Childhood Atopy: Why Maternal Smoking History Matters
Allergy & Immunologyatopic dermatitisprenatal care

High-Dose Prenatal Vitamin D and Childhood Atopy: Why Maternal Smoking History Matters

By MedXY|Jan 20, 2026

Recent findings from the COPSAC2010 trial and EDEN cohort suggest that high-dose prenatal vitamin D’s protective effect against atopic dermatitis is significantly enhanced in children of mothers exposed to tobacco, highlighting a pote

Rocatinlimab (OX40 blockade) delivers clinically meaningful benefit in moderate-to-severe atopic dermatitis: results from ROCKET-IGNITE and ROCKET-HORIZON
Dermatologyatopic dermatitis

Rocatinlimab (OX40 blockade) delivers clinically meaningful benefit in moderate-to-severe atopic dermatitis: results from ROCKET-IGNITE and ROCKET-HORIZON

By MedXY|Dec 1, 2025

Two global phase 3 trials show rocatinlimab, an anti‑OX40 therapy, produced statistically significant improvements in EASI‑75 and vIGA‑AD 0/1 at 24 weeks versus placebo with a generally acceptable safety profile.

SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes
Dermatologyatopic dermatitisDPP‑4 inhibitors

SGLT2 Inhibitors Linked to Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes

By MedXY|Nov 1, 2025

A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-r

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study
Dermatologyatopic dermatitisdiabetes

SGLT2 Inhibitors Associated with Lower Risk of New-Onset Atopic Dermatitis in People with Type 2 Diabetes: Nationwide Active-Comparator Cohort Study

By MedXY|Nov 1, 2025

A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities